Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy

• Published in: Haematologica (Roma) Vol. 109; no. 8; pp. 2436 - 2444
• Main Authors: Dargaud, Yesim, Leuci, Alexandre, Ruiz, Alejandra Reyes, Lacroix-Desmazes, Sebastien
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 01-08-2024; Fondazione Ferrata Storti
• Subjects: Animals; Clinical Trials as Topic; Factor VIII - immunology; Factor VIII - therapeutic use; Hemophilia A - drug therapy; Humans; Life Sciences; Spotlight Review; von Willebrand Factor - chemistry; von Willebrand Factor - metabolism; von Willebrand Factor - therapeutic use; BIVV001; haemophilia A; XTEN; VWF D'D3; factor VIII; Efanesoctocog alfa
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2023.284498

Efanesoctocog alfa (Altuviiio,TM Sanofi-SOBI) is a B domain-deleted single-chain Factor VIII (FVIII) connected to D'D3 domain of von Willebrand Factor (vWF). Its ingenious design allows efanesoctocog alfa to operate independently of endogenous vWF and results in an outstanding 3-4 times longer half-life compared to standard and extended half-life (EHL) FVIII products. The prolonged half-life ensures sustained high levels of factor activity, maintaining normal to near-normal ranges for the majority of the week, facilitating the convenience of once-weekly administration. Efanesoctocog alfa received regulatory approval in 2023 for application in both adults and children with inherited hemophilia A in the United States and Japan. Its sanctioned use encompasses both prophylaxis and 'on demand' treatment for bleeding episodes. The European Medicines Agency (EMA) is currently undertaking a comprehensive review of Altuviiio. TM This comprehensive review focuses on the immunological profile of efanesoctocog alfa, a highly sophisticated new class of EHL FVIII molecule. The integration of the vWF D'D3 domain, XTEN polypeptides, and potential regulatory T-cell epitopes within various segments of efanesoctocog alfa collectively serves as a mitigating factor against the development of a neutralizing T-cell-mediated immune response. We hypothesize that such distinctive attribute may significantly reduce the risk of neutralizing antibodies, particularly in previously untreated patients. The discussion extends beyond regulatory approval to encompass the preclinical and clinical development of efanesoctocog alfa, including considerations for laboratory monitoring. The review also highlights areas that warrant further investigation to deepen our understanding of this groundbreaking therapeutic agent.